Lundbeck Advances Parkinson's Research with New Data on Lu AF28996 #USA #Parkinson's_Disease #Lundbeck #Valby #Lu_AF28996

Lundbeck Unveils Promising Phase Ib Results for Lu AF28996 in Advanced Parkinson's Disease #Denmark #Parkinson's_Disease #Lundbeck #Valby #Lu_AF28996

Lundbeck to Present Groundbreaking Movement Disorder Research at MDS® 2026 Conference #Denmark #Lundbeck #Valby #Amlenetug #MDS_2026

Lundbeck's Insights on Movement Disorders at MDS® 2026: Focus on MSA and Parkinson's Disease #Denmark #Movement_Disorders #Lundbeck #MSA #Valby

Lundbeck's Phase IV THRIVE Trial Results Show Promise for Eptinezumab in Migraine Treatment #Denmark #Lundbeck #Valby #Vyepti #Eptinezumab

Lundbeck's Phase IV THRIVE Trial Reveals Promising Results for VYEPTI® in Migraine Patients #Denmark #Lundbeck #Valby #Migraine #Vyepti

Police respond after man sets himself on fire at agency #denmark #police #Valby

🇩🇰 Mand i Valby har sat ild til sig selv, politi massivt til stede

#NordicNews #Nyheder #Valby #DKMedier

Last Participant Randomized in Phase III DEEp SEA Trial for Bexicaserin in Dravet Syndrome #Denmark #Dravet_Syndrome #Lundbeck #bexicaserin #Valby

Lundbeck Reaches Significant Milestone in Bexicaserin Trial for Dravet Syndrome #Denmark #Dravet_Syndrome #Lundbeck #bexicaserin #Valby

Lundbeck's Asedebart Receives FDA Orphan Drug Designation for Cushing's Syndrome #Denmark #Lundbeck #Valby #Cushing's_Syndrome #asedebart

Lundbeck's Asedebart Receives Orphan Drug Status for Rare Hormonal Disorder #USA #Lundbeck #Valby #Cushing's_Syndrome #asedebart

Lundbeck Unveils Key Insights on Bexicaserin's Unique Mechanism at the European Epilepsy Congress #Denmark #Lundbeck #bexicaserin #Valby #DEEp_Program

Lundbeck to Showcase Bexicaserin's Innovative Dual Action Mechanism at European Epilepsy Congress #Denmark #Lundbeck #bexicaserin #Valby #Epilepsy_Congress